Top Markets
#1 TENDIES TENDIES +42.50%
#2 ICON ICON +27.31%
#3 Threshold Network Threshold Network +26.12%
#4 Cash Cat Cash Cat +25.97%
#5 Asteroid Shiba Asteroid Shiba +17.20%
#6 OSK OSK +15.67%
#7 MarsCoin MarsCoin +12.17%
#8 Ape and Pepe Ape and Pepe +9.71%
#9 Pirate Chain Pirate Chain +9.26%
#10 Kite Kite +9.02%
Coin of the day
TENDIES TENDIES
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
AIM Vaccine Co., Ltd. AIM Vaccine Co., Ltd.

AIM Vaccine Co., Ltd.

6660
Classement en actions #16674
Operating within the People's Republic of China, AIM Vaccine Co., Ltd.... Operating within the People's Republic of China, AIM Vaccine Co., Ltd. specializes in the entire lifecycle of human vaccine products, encompassing their discovery, production, and market introduction. Among its current developments, the company is advancing Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA vaccine candidates for COVID-19, both currently undergoing Phase III clinical trials. Its comprehensive portfolio also features vaccines targeting a range of other conditions, such as an EV71-CA16 Bivalent vaccine for Hand, Foot, and Mouth Disease (HFMD), and both Conjugate and Polysaccharide versions for pneumococcal disease. Further offerings include a Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine, various Diphtheria, Tetanus, and Pertussis (DTP) formulations (including DTP combined with Haemophilus Influenzae type B, acellular pertussis, and absorbed tetanus), a Haemophilus Influenzae Type B (Hib) vaccine, and both traditional freeze-dried and innovative mRNA human rabies vaccines. Beyond these, AIM Vaccine is actively developing several other vaccines, including 2- and 3-valent Human Papillomavirus (HPV) vaccines, a Tetravalent Meningococcal Conjugate vaccine, a Tetravalent Influenza vaccine, mRNA-based vaccines for Shingles/Herpes Zoster and Respiratory Syncytial Virus (RSV), a live attenuated parotitis vaccine, and an ACYW135 meningococcal polysaccharide vaccine. Established in 2011 and headquartered in Beijing, PRC, the company adopted its current name, AIM Vaccine Co., Ltd., in September 2020, having previously operated as Beijing AIM Biological Vaccine Technology Group Co., Ltd.
Prix de l'action
$0.22770869
Capitalisation boursière
$278.82M
Changement (1 jour)
3.79%
Changement (1 an)
-64.80%
Pays
CN
Échange AIM Vaccine Co., Ltd. (6660)

Catégorie

Healthcare
Bénéfices pour AIM Vaccine Co., Ltd. (6660)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de AIM Vaccine Co., Ltd., les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour AIM Vaccine Co., Ltd. de 2026 à 2026
Bénéfices à la fin de chaque année
Année Bénéfices Changez
Pas assez de données pour les dates fournies.
Bénéfices des entreprises similaires ou concurrentes
Entreprise Bénéfices Différence de bénéfices Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH